Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Mass. , Aug. 4, 2015  Blueprint Medicines ... developing highly selective kinase drugs for genomically defined diseases, ... officer, will present a company overview at the 2015 ... at 1:20 p.m. EDT. A live webcast ... Investors section of the Blueprint Medicines website at ...
(Date:8/3/2015)... Aug. 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... for the second quarter 2015 on Monday, August 10, ... Helen Torley , president and chief executive officer, will ... will release financial results for the second quarter 2015. ... the "Investors" section of Halozyme,s corporate website and a ...
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Inc ., has reported a smaller net loss of $5.2 million, ... molecular diagnostic revenue during the third quarter of 2006. , ,Third ... loss of $7.4 million, or 18 cents per share, for the ... company's third-quarter net loss improved 37 percent from its pro forma ...
... United States economy is cooling off just a bit, but ... not one of them, according to venture investment trackers. ... the third quarter of 2006, which represents a decline in ... PricewaterhouseCoopers and the National Venture Capital Association ...
... you follow Wisconsin's race for governor only by watching ... about gun control, the death penalty, abortion rights, stem ... gay marriage. , ,But when you spend time talking ... them, you get a dramatically different picture. Their priorities ...
Cached Biology Technology:Third Wave reports $5.2M third quarter loss 2Venture capital above $6B for third straight quarter 2Venture capital above $6B for third straight quarter 3What citizens don't ask political candidates 2What citizens don't ask political candidates 3
(Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... New research published in the international journal Neurobiology ... that being physically fit helps the brain function at ... for Medical Research Senior Scholar, Poulin finds that physical ... a result, cognitive abilities. "Being sedentary is now ...
... A study by researchers at the UC Davis M.I.N.D. Institute ... number children born in California with autism since 1990 cannot ... diagnosed or counted and the trend shows no sign ... the journal Epidemiology , results from the study also ...
... an international journal that publishes original research contributions ... entomology, plant pathology, virology, nematology and weed sciences, ... Emphasis is on new approaches in the control ... also publishes invited reviews, research notes and book ...
Cached Biology News:Research finds older women who are more physically fit have better cognitive function 2Study shows California's autism increase not due to better counting, diagnosis 2Study shows California's autism increase not due to better counting, diagnosis 3Springer expands its portfolio in plant sciences with Phytoparasitica 2
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... Kit is based on quantification of the ... and free orthophosphate. The rapid color formation ... on a spectrophotometer (600-660 nm) or on ... kits have been optimized to offer superior ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
Biology Products: